Show an ad over header. AMP

I am the FIRST

New, unproven Alzheimer's drug could blow up health spending

Reproduced from KFF and Bernstein; Chart: Axios Visuals

Biogen's new Alzheimer's treatment could be experts' nightmare drug spending scenario: An extremely expensive product that millions of desperate patients could be eligible for — and it may not even work.

Why it matters: Alzheimer's is a devastatingly common disease with no cure. But the FDA's decision this week paved the way for a free-for-all in which taxpayers foot most of the enormous bill for a drug that hasn't been proven effective.


Driving the news: The FDA approved Aduhelm for all Alzheimer's patients, rather than the narrower subset it was tested against.

  • It's estimated that around 6 millionAmericans currently have the disease, most of whom are covered by Medicare.

By the numbers: Around 500,000 Americans are diagnosed with Alzheimer's each year, and the company announced that the drug costs $56,000 annually.

  • Patients would receive monthly infusions of the drug, which they'd likely need long-term. An Alzheimer's patient lives, on average, an additional three to 11 years after their diagnosis, per the Mayo Clinic.
  • If half of the newly eligible Americans in a year began treatment with Aduhelm, the cost would be $14 billion — roughly equivalent to Medicare Part B spending in 2019 on the next 8 products combined, per a Bernstein analysis. Total Part B spending in 2019 was $37 billion.
  • But that's a conservative estimate of annual spending on Aduhelm, as it only applies to half of one year's worth of newly diagnosed Alzheimer's patients.

Yes, but: It will likely take a while for the health system to build up enough capacity to handle the influx of eligible patients.

  • And some private insurers may limit eligibility. Steve Miller, chief clinical officer at Cigna, said yesterday that he expected Cigna and most other insurers will pay for the drug only for patients meeting certain criteria, per the NYT.

Between the lines: The numbers alone could give new ammunition to advocates who argue that drug prices are too high and should be limited.

  • "It's unconscionable to ask seniors and taxpayers to pay $56,000 a year for a drug that has yet to be proven effective. Medicare must be able to negotiate a fair price for prescription drugs," tweeted Senate Finance Committee Chairman Ron Wyden.
  • But politicians may find it hard to take on the narrative that the treatment is anything but a long-sought beacon of hope for Alzheimer's patients.

What they're saying: “It’s always been the worry that if you get a super expensive drug that is targeted toward a huge population, that that is going to be a turning point in how we deal with health care spending,"said Walid Gellad,a health policy professor at the University of Pittsburgh. "And that’s what this drug is.”

Go deeper: Aduhelm's price to squeeze Medicare and patients

4 ffp

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories